

CureVac to Present at the 8th Annual Leerink Partners Global Healthcare Conference

TÜBINGEN, Germany / BOSTON, MA, February 19, 2019 – CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Dan Menichella, Chief Executive Officer, will present a corporate overview at the 8th Annual Leerink Partners Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 1:50 p.m. ET.

A live broadcast of the presentation will be available at www.curevac.com/en/newsroom/curevacevents. An archived replay of the presentation will be available on the company's website for approximately 3 months following the presentation.

About CureVac AG

CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 19 years' expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies. To date, CureVac has received approximately \$420 million (€400 million) in equity investments including significant investments from SAP founder Dietmar Hopp's Dievini and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, Arcturus Therapeutics, Acuitas, and the Bill & Melinda Gates Foundation.

For more information, please visit www.curevac.com or follow us on Twitter at [@CureVacAG](https://twitter.com/CureVacAG).

Investor Contact

Matthew Beck, Vice President Investor Relations
CureVac AG, Boston, MA, United States
T: +1 917-415-1750
matthew.beck@curevac.com